Polyherbal formulation exerts wound healing, anti-inflammatory, angiogenic and antimicrobial properties: Potential role in the treatment of diabetic foot ulcers.
Areca nut
Diabetes
HaCaT
Herbal formulation
Keratinocytes
Thai medicinal plants
Journal
Saudi journal of biological sciences
ISSN: 1319-562X
Titre abrégé: Saudi J Biol Sci
Pays: Saudi Arabia
ID NLM: 101543796
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
20
01
2022
revised:
27
04
2022
accepted:
26
05
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
ppublish
Résumé
Diabetic foot ulcer (DFU) is a common and devastating complication in diabetic patients and is associated with an elevated risk of amputation and mortality. DFU remains a major therapeutic challenge due to poor understanding of its underlying pathogenesis. This complication is characterized by impaired wound healing; however, mechanisms causing this impairment are complicated and involve interactions between many different cell types and infections. In addition to other conventional DFU treatments, herbal foot baths are also common, although little is known about their mechanisms of action, and they contain a wide variety of herbal ingredients. In this study, we aimed to examine the effects of three polyherbal formulations consisting of medicinal plants used in traditional Thai herbal foot baths on wound healing, anti-inflammation, angiogenesis, and extracellular matrix modulation using high-concentration glucose-treated human keratinocytes, in addition to antibacterial evaluation. Our results showed that formulation 3 (F3) possessed the greatest potential to restore the impairment of keratinocytes caused by high glucose concentrations. We found that F3 could inhibit the growth of
Identifiants
pubmed: 35721231
doi: 10.1016/j.sjbs.2022.103330
pii: S1319-562X(22)00246-7
pmc: PMC9198379
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103330Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Diabet Med. 2006 Jun;23(6):594-608
pubmed: 16759300
Curr Diab Rep. 2018 Jan 23;18(1):2
pubmed: 29362914
Diabetes Metab Syndr. 2015 Jul-Sep;9(3):192-9
pubmed: 25982677
Ther Adv Endocrinol Metab. 2018 Jan;9(1):29-31
pubmed: 29344337
Diabetes Res Clin Pract. 2018 Apr;138:271-281
pubmed: 29496507
Cell Physiol Biochem. 2015;37(3):940-54
pubmed: 26381245
Adv Ther. 2014 Aug;31(8):817-36
pubmed: 25069580
Curr Vasc Pharmacol. 2015;13(4):520-5
pubmed: 25360838
Ann Med. 2017 Mar;49(2):106-116
pubmed: 27585063
Front Pharmacol. 2017 Nov 07;8:798
pubmed: 29163178
J Diabetes Res. 2018 Mar 01;2018:1654530
pubmed: 29687009
Front Physiol. 2019 Jan 28;10:24
pubmed: 30745880
J Tradit Chin Med. 2017 Dec;37(6):735-745
pubmed: 32188182
Pharmaceuticals (Basel). 2021 Sep 04;14(9):
pubmed: 34577601
Pharm Biol. 2016 Nov;54(11):2606-2615
pubmed: 27180784
Lancet. 2005 Nov 12;366(9498):1736-43
pubmed: 16291068
Biomed Pharmacother. 2019 Apr;112:108615
pubmed: 30784919
J Clin Invest. 2007 May;117(5):1219-22
pubmed: 17476353
Lancet. 2005 Nov 12;366(9498):1719-24
pubmed: 16291066
Food Chem Toxicol. 2008 Oct;46(10):3227-39
pubmed: 18725264
Fitoterapia. 2009 Mar;80(2):102-4
pubmed: 19022354
JAMA. 2005 Jan 12;293(2):217-28
pubmed: 15644549
Expert Rev Mol Med. 2009 Jan 13;11:e2
pubmed: 19138453
Diabetes Metab Res Rev. 2001 Jul-Aug;17(4):246-9
pubmed: 11544609
BMC Surg. 2008 Feb 29;8:5
pubmed: 18312623
Evid Based Complement Alternat Med. 2018 Feb 19;2018:3142073
pubmed: 29670658
BMC Complement Med Ther. 2020 Feb 14;20(1):55
pubmed: 32059725